CanSinoBIO’s NDA for Td5cp Adolescent and Adult Accepted, Further Strengthening Its Diversified Vaccine Pipeline

HONG KONG, August 16, 2026 – (ACN Newswire) – On August 16, 2026, CanSino Biologics Inc. (“CanSinoBIO”; HKEX: 06185/SHSE: 688185) announced that the New Drug Application (NDA) for its Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, Adsorbed (for people aged six years and above…
Read More